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Available online 3 May 2017The rationale for B cell depletion therapy with rituximab in primary Sjögren's syndrome relies upon the
well-established role of B cell hyperactivity in immunopathogenesis. In line with this notion, several biomarkers
of B cell activity are signiﬁcantly affected by treatment, both in the target organs and periphery. In contrast to
most biological outcomes, clinical outcomes are not consistent between studies. Although two large RCTs did not
meet their primary endpoint, several beneﬁcial clinical effects of treatment have been shown. As discussed in this
review, differences in study design and patient characteristics could explain the variation in results. Interestingly,
a newly developed composite endpoint of subjective and objective outcomes did show a signiﬁcant effect of ritux-
imab in one of the large RCTs. Response predictors need to be identiﬁed to deﬁne more targeted inclusion criteria
and achieve precisionmedicine. The positive effects seen on biological and clinical parameters warrant future stud-
ies to investigate this promising treatment modality.
© 2017 Elsevier Inc. All rights reserved.Keywords:
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Efﬁcacy1. Introduction
Primary Sjögren's syndrome (pSS) is a systemic autoimmune
disease with a heterogeneous clinical presentation. Predominant
symptoms of pSS are dryness of mouth and eyes, but many patients
also suffer from extraglandular symptoms, including chronic
fatigue, arthralgia and involvement of lungs, skin, kidneys and the
nervous system. Dysfunction of exocrine glands is accompanied by
periductal mononuclear inﬁltration of these glands, mainly by CD4+ T
cells and B cells. Involvement of B cells in pSS pathogenesis is further
illustrated by the presence of autoantibodies directed against
SS-A/Ro and/or SS-B/La, elevated levels of rheumatoid factor (RF),
hypergammaglobulinemia, elevated levels of Bruton's tyrosine kinase
in B cells and a signiﬁcantly increased risk of Non-Hodgkin B cell
lymphoma, predominantly mucosa-associated lymphoid tissue
(MALT) lymphoma [1,2].
The prominent role of B cell hyperactivity in pSS pathogenesis
provides a rationale for the use of rituximab, a humanized anti-CD20
monoclonal antibody, to treat this disease. Binding of rituximab to
CD20-expressing B cells results in a signiﬁcant depletion of these cells
via antibody-dependent cellular cytotoxicity, complement mediated
cytotoxicity and apoptosis [3]. Plasma cells are not directly depleted by
rituximab, because expression of CD20 is downregulated when B cellslogy and Clinical Immunology,
roningen, HPC AA21, PO-Box
stappen).differentiate towards plasma cells, but formation of new plasma cells
may be impaired by B cell depletion therapy. Although initial studies in
pSS showed improvement of both subjective and objective parameters
[4–7], two large placebo-controlled trials [8,9] did not conﬁrm all
promising results of the earlier studies. Possible explanations for this
discrepancy are heterogeneity in patient characteristics, primary end
points and background medication use, which will all be discussed in
this review. Consensus on the efﬁcacy of rituximab in pSS is currently
lacking, but treatment results in several clinical, biological and histologi-
cal improvements. Furthermore, treatment studieswith rituximab in pSS
provided insights in the pathogenic mechanisms of the disease and
post-hoc analyses of biological parameters have identiﬁed possible
biomarkers that can predict response. These biomarkers may character-
ize subgroups of pSS patients that beneﬁt from rituximab before start of
treatment. Future studies with B cell-targeting therapy can contribute to
identiﬁcation of new predictors of response, as well as development of
sensitive and accurate outcome measures for future clinical trials in pSS.
2. Effects of rituximab on B cell hyperactivity
2.1. Systemic markers of B cell hyperactivity
Several biomarkers of B cell activation, including gammaglobulins,
autoantibodies (RF, anti-SS-A/Ro, anti-SS-B/La), β2-microglobulin, free
light chains and B cell activating factor (BAFF/Blys) have been studied
in the context of rituximab treatment in pSS (Fig. 1). A small but signiﬁ-
cant gradual decrease in total serum IgG after 24 weeks of treatment is
seen in larger studies (Table 1) [4,8,10]. At the same time, a decrease in
RF levels (up to 50%) is observed (Table 1) [4,6,10–12]. Interestingly,
Fig. 1. Effects of rituximab treatment on immunopathogenesis of pSS. Cytokine production by B cells and (T cell-dependent) formation of plasmablasts and short-lived plasma cells are
impaired by B cell depletion therapy with rituximab. B cell hyperactivity is reduced, as reﬂected by lowering of serum IgG, anti-SSA, free light chains and rheumatoid factor. Numbers
of circulating Tfh cells and serum levels of IL-21 are also decreased. In salivary gland tissue, formation of ectopic lymphoid tissue and germinal centers is impaired. FLCs: free light
chains, RF: rheumatoid factor.
63G.M. Verstappen et al. / Clinical Immunology 182 (2017) 62–71Dass et al. found that a non-responder had less reduction in RF after
treatment compared with responders [6]. Following B cell repopulation,
RF levels rise again and this rise can predict relapse of clinical symptoms
[5,12]. Similar to ﬁndings in rheumatoid arthritis (RA), combined
presence of RF and disease-speciﬁc autoantibodies (anti-SS-A/Ro,
anti-SS-B/La) may result in higher disease activity in pSS as well [13].
The mechanism behind this synergistic effect is unknown, but
crosslinking and/or stabilization of immune complexes, consisting of
autoantigens and autoantibodies, by RF is likely involved. In combination
with the ﬁnding that higher RF levels seem to increase the risk of
lymphoma [14], these data suggest that lowering RF levels by rituximab
treatment is of clinical importance, as it may protect against disease
progression and/or lymphoma development in pSS.
Several studies assessed the effect of rituximab on anti-SS-A/Ro or
anti-SSB/La serum levels in pSS patients. While three studies did not
ﬁnd signiﬁcant changes in anti-SS-A/Ro or anti-SS-B/La autoantibodiesTable 1
Main biological effects of rituximab treatment analyzed in prospective clinical studies.
Study population Patients treated (n) IgG RF
Pijpe et al. [11] 15 = ↓a
Devauchelle-Pensec et al. [15] 16 = =
Dass et al. [6,55] 8 ↓b ↓
Meijer et al. [68] 5 NA ↓
Meijer et al. [4] 20 ↓ ↓
Gottenberg et al. [48] 78 NA NA
Carubbi et al. [7] 19 = =
St. Clair et al. [16] 12 NA ↓b
Devauchelle-Pensec et al. [8] 63 ↓ NA
Meiners et al. [10] 28 ↓ ↓
Bowman et al. [9] 67 NA NA
Arrows indicate a decrease. NA = not available.
a Only in patients with MALT/pSS.
b Not statistically signiﬁcant.after treatment [7,15,16], we found a signiﬁcant reduction of ±25% in
anti-SS-A/Ro and anti-SS-B/La titers at 16 weeks after treatment
(Table 1) [17]. The discrepancy between studiesmaybe explained by dif-
ferences in study population size, baseline systemic disease activity, time
point of measurements, or differences in reliability of the immunoassay,
but methods for anti-SS-A/Ro and anti-SS-B/La measurement were not
speciﬁed in most studies. The observed reduction in autoantibodies is
likely a result of decreased generation of short-lived plasma cells, due
to depletion of CD20+ precursor cells, and/or direct depletion of CD20-
expressing (short-lived) plasma cells. There is evidence that anti-SSA/
Ro60 antibody production depends –at least partially– on clonal turn-
over of short-lived plasma cells and this may also be true for other auto-
antibodies [18]. B cell depletion therapy can therefore directly affect
autoantibody production in pSS patients.
In addition to gammaglobulin and autoantibody levels, other indica-




NA ↓ 3 (20) 3 (20)
↓b ↓ 0 (0) 0 (0)
NA NA NA NA
NA NA 0 (0) 0 (0)
NA ↓ 0 (0) 0 (0)
NA NA 29 (37) 17 (22)
= ↓ 0 (0) 19 (100)
= NA 8 (67) 3 (25)
NA ↓ 10 (19) 17 (32)
↓ NA 0 (0) 0 (0)
NA NA 39 (58) 7 (10)
64 G.M. Verstappen et al. / Clinical Immunology 182 (2017) 62–71treatment. β2-microglobulin levels show a ‘delayed’ drop at 16 weeks
after treatment [8,12], which was not seen at 6 or 12 weeks after rituxi-
mab treatment [8,11]. Serum immunoglobulin free light chains (FLCs)
are also affected by rituximab and decrease signiﬁcantly from week 5
up to week 48 after treatment (unpublished data), in line with ﬁndings
in RA [19]. Both β2-microglobulin and FLC baseline levels in serum of
pSS patients are positively correlated to ESSDAI scores [20], suggesting
that there is a link between the degree of B cell activation and systemic
disease activity. Serum levels of several B cell-associated cytokines,
including IL-6, GM-CSF, TNF-α and IL-10, are also lowered by rituximab
[21]. Whether this decrease is the consequence of removal of cytokine-
producing B cells, or is caused by indirect effects of B cell depletion on
cytokine production by other cells is not yet known. In contrast to the
B cell-associated cytokinesmentioned above, serum BAFF levels increase
after B cell depletion therapy, likely due to unavailability of BAFF
receptors as a consequence of the absence of B cells [22]. This rise in
BAFF levels may be unfavorable for the patient due to enhanced survival
of autoreactive B cell clones and skewing of newly formed B cells
towards an autoreactive phenotype [23,24]. Therefore, the efﬁcacy of
therapy combining B cell depletion and BAFF-blockade is currently
under investigation (NCT02631538).
In summary,most biomarkers of B cell activation in the circulation are
decreased byB cell depletion therapy (Fig. 1). Lowering of B cell activation
likely contributes to amelioration of systemic disease activity in pSS
patients, due to lower levels of autoantibodies and pro-inﬂammatory
cytokines.
2.2. Histological markers of B cell hyperactivity
B cells inﬁltrate the glandular tissue of pSS patients, accumulate
around the ductal epithelium and, togetherwith stromal cells and follic-
ular dendritic cells, orchestrate formation of ectopic lymphoid tissue.
Importantly, rituximab clearly reduces the total number and proportion
of inﬁltrating B cells in both minor and major salivary glands (Table 1)
[7,25,26]. In addition, as shown inminor salivary gland tissue, rituximab
decreases mRNA expression of lymphotoxin (LT)-α and -β, important
for lymphoid organogenesis [7]. The reduction of lymphotoxin is likely
a direct result of lower B cell numbers in the glands, as the heterodimer
LTα1β2 ismainly produced by B cells [27]. Lowering of B cell numbers is
further accompanied by a decline in germinal centers located within
ectopic lymphoid tissue of the glands [28]. This decline is likely caused
both by direct depletion of B cells, as well as reduced presence of Tfh
cells (ﬁg. 1) [17].
B cells often inﬁltrate the ductal epithelium of the salivary glands,
resulting in the development of lymphoepithelial lesions. Most of these
intra-epithelial B cells belong to a unique subset of cells expressing
FcRL4 and these cells possibly function as precursor cells for MALT
lymphoma [29]. We have found that intra-epithelial FcRL4+ B cells are
almost completely depleted by rituximab [29]. Furthermore, rituximab
treatment reduces the severity of lymphoepithelial lesions, and concom-
itantly leads to restoration of the epithelium [25]. It would be of value to
studywhether rituximab-treatedpatients developMALT-lymphoma less
frequently than untreated patients.
As expected, plasma cells can persist in parotid glands of pSS patients
despite B cell depletion therapy, since they lack expression of CD20 [30].
However, it is not known if absolute numbers of plasma cells in salivary
glands are affected by rituximab and whether this is associated
with response to treatment. In synovial tissue of RA patients, a larger
decrease in synovial plasma cells was observed in responders versus
non-responders [31]. Therefore, it is of interest to study local plasma
cell numbers in pSS patients after rituximab.
3. Effects of rituximab on the CD4+ T cell compartment
Depletion of B cells abrogates antigen presentation and cytokine pro-
duction by these cells and rituximab treatment may therefore affectother cell types, in particular CD4+ T cells (Fig. 1) [32]. Patients with
pSS have elevated proportions of circulating T follicular helper (cTfh)
cells, deﬁned as CXCR5+PD-1+CD45RA−CD4+ cells, compared with
healthy controls [17,33,34]. The B cell hyperactivity that is present in
pSS patients may favor differentiation of Tfh cells through secretion of
IL-6 by activated B cells in conjunction with high expression of co-
stimulatorymolecules (e.g., CD40, ICOS-L) [35,36]. Tfh cells subsequently
activate B cells and promote germinal center formation and plasma cell
formation [36], providing a positive-feedback loop. We have recently
shown that cTfh cells, and to a smaller extent also Th17 cells, are reduced
by rituximab [17]. The decrease in cTfh cells correlates with lowering of
ESSDAI scores, emphasizing their potential role in the disease process.
Reduced frequencies and numbers of cTfh cells and Th17 cells during B
cell depletion are accompanied by decreased serum levels of IL-21 and
IL-17. Th17 cells in minor salivary glands are also reduced by rituximab,
but the effect on local Tfh cells is not known yet [37,38]. Depletion of the
small fraction of Th17 cells that co-expresses CD20may contribute to the
decrease in Th17 cells [39]. Thus, taking all the biological effects of ritux-
imab on (T cell-mediated) B cell hyperactivity together, these ﬁndings
may –at least in part– underlie beneﬁcial clinical outcomes of rituximab
in pSS patients.
4. Clinical efﬁcacy of rituximab in primary Sjögren's syndrome
Several open-label and randomized controlled trials have been
performed to date, including two larger RCTs: the TEARS and
TRACTISS trials [8,9]. In Tables 2 and 3, population characteristics and
clinical outcomes of all prospective clinical trials reported in literature
are summarized. Despite the generally acknowledged beneﬁcial effects
of rituximab treatment on biological parameters, clinical outcomes vary
between studies.
4.1. Effects on exocrine gland function and sicca symptoms
Objective measures of salivary gland function include unstimulated
whole salivary ﬂow (UWS) and stimulated whole salivary ﬂow (SWS).
UWS depends mainly on submandibular gland function, while SWS
depends on both submandibular and parotid gland function. The ratio of
parotid and submandibular saliva in SWSdepends on themethod of stim-
ulation (mechanical vs. citric acid stimulation). UWS and SWS are both
outcomes of interest. However, it is important to realize that patients
show substantial intra-individual variability in salivary ﬂow, resulting in
a large standard deviation [40,41]. Therefore, adequate sample sizes are
needed to show the effect of treatment on salivary gland function.
Meijer et al. and Carubbi et al. showed signiﬁcant improvement in
UWS after rituximab treatment [4,7]. In other trials, including the
TEARS trial, no effect on UWS was observed [6,8,11,15]. Although the
mean baseline UWS in the TEARS trial was comparable to the study of
Meijer et al., the standard deviation was twice as high, which may
inﬂuence the power of their analysis. St. Clair et al. did not ﬁnd an effect
on UWS, but included patients with low to absent UWS at baseline,
who therefore may have had irreversible destruction of glandular
parenchyma [16]. Recently, Bowman et al. showed that UWS of patients
in the rituximab group of the TRACTISS trial remained stable, while the
placebo group deteriorated [9].
Only few studiesmeasured the effect of rituximab on SWS. Pijpe et al.
showed that rituximab improved stimulated submandibular/sublingual
salivary ﬂow only in patients with residual salivary gland function at
baseline (SWS N 0.10 ml/min) [11]. Similarly, in the RCT by Meijer et al.
only patients with a SWS ≥ 0.15 ml/min were included, and SWS was
signiﬁcantly increased in the rituximab group, while it deteriorated in
the placebo group [4]. Unfortunately, recent RCTs did not measure SWS.
Currently, there is a growing interest in salivary gland ultrasound for
assessment of the salivary gland structure, as it is non-invasive and inex-
pensive. The ﬁrst study using ultrasound showed a reduction in size of
the parotid and submandibular glands after rituximab treatment [32].
Table 2
Study population characteristics.















Pijpe et al. [11] (early pSS group) Open label 8 0 46 ± 12 2 ± 1 NA 100 19 ± 5 0.04 (0–0.19) 0.38 (0.2–1.38)
Pijpe et al. [11] (MALT/pSS group) Open label 7 0 54 ± 10 7 ± 4 NA 100 13 ± 6 0 (0–0.5) 0.01 (0–0.47)
Devauchelle-Pensec et al. [15] Open label 16 0 55 ± 13 13 ± 10 NA 81 20 ± 13 0.1 ± 0.1 NA
Dass et al. [6,55] RCT pilot 8 9 51 (22–64) 7 (1–18) NA 100 19 (12–29) NA NA
Meijer et al. [68] Open label Re-treatment 5 0 a a a a a NA 0.09 ± 0.07b
Meijer et al. [4] and Moerman et al. [49] RCT 20 10 43 ± 11 5 ± 4 8 (4–13) 100 23 ± 8 0.17 ± 0.19 0.70 ± 0.57
Gottenberg et al. [48] Registry 78 0 60 (29–83) 12 (3−32) 11 (2−31) 69 NA NA NA
Meiners et al. [5] Open label Re-treatment 28 0 43 ± 14 7 ± 4 8 ± 5 100 23 ± 7 0.16 ± 0.18 0.42 ± 0.37
Carubbi et al. [7] Open label 19 22 40 (27–53) 1 (1–2) 20 (6–41) NA NA 0.08 ± 0.04 NA
St. Clair et al. [16] Open label 12 0 51 (34–69) 8 (2–18) NA 83 NA 0.03 (0.0–0.22) 0.05 (0.0–0.65)
Devauchelle-Pensec et al. [8] RCT 63 57 53 ± 13 5 ± 5 10 ± 7 81 16 ± 6 0.2 (0.4) NA
Bowman et al. [9] RCT 67 66 54 ± 12 5 ± 5 5 ± 5 99 18 ± 7 0.08 (0.08) NA
Results are presented as mean ± SD or median (range). For controlled studies, patient characteristics are presented for the rituximab-treated group.
a See Pijpe et al. [11].




























Fatigue Pain ESSDAI ESSPRI SF-36
RTX Control
Pijpe et al. [11]
Early pSS group






MFI GF SF-36 BP = NA NA Physical functioning
Vitality Health change
Other domains =
Pijpe et al. [11]
MALT+ pSS group
Open label 7 0 12 High UWSF =





MFI GF = SF-36 BP= NA NA All domains =
Devauchelle-Pensec et al. [15,69] Open label 16 0 36 Low UWSF = Schirmer = VAS VAS NA NA All domains except physical functioning
MCS PCS
Dass et al. [6,55] RCT pilot 8 9 26 High UWSF = Schirmer = NA VAS d
PROFAD-SSI d
VAS = NA NA f
Meijer et al. [68] Open label
Re-treatment
5 0 48 High SWSF NA Oral MFI GF NA NA NA Physical functioning






MFI GF NA f NA Total score d Vitality a
Gottenberg et al. [48] Registry 78 0 152b High NA NA NA NA NA NA NA
Meiners et al. [5] Open label
Re-treatment
28 0 48 High SWSF = NA Oral = c
Ocular = c
MFI GF c NA NA
Carubbi et al. [7] Open label 19 22 120 High UWSF d,f f f f VAS f NA NA
St. Clair et al. [16] Open label 12 0 52 High UWSF =
SWSF =
Schirmer = Oral subscores
Ocular =
VAS VAS = NA NA Vitality MCS = PCS =
Devauchelle-Pensec, [8] RCT 63 57 24 High UWSF = Schirmer = f f VAS = = NA MCS = PCS =
Bowman et al. [9] RCT 67 66 48 High UWSF = e Schirmer = = VAS =
PROFAD-SSI =
VAS = = = All domains =
High-dose: 375 mg/m2/week (4×) or 1000 mg/m2/two weekly (2×). Low-dose: 375 mg/m2/week (2×).
Green arrows indicate signiﬁcant improvements.
RTX: rituximab. NA: not available. VAS: visual analogue scale. ESSDAI: European League Against Rheumatism (EULAR) Sjögren's syndrome (SS) disease activity index. ESSPRI: EULAR SS patient reported index. UWSF: Unstimulated whole salivary
ﬂow. Stim SM/SL: Stimulated submandibular/sublingual salivary ﬂow. SWSF: Stimulated whole salivary ﬂow. RB: Rose Bengal. LG: Lissamin Green. MFI GF: Multidimensional Fatigue Index, General Fatigue domain. PROFAD: Proﬁle of Fatigue and
Discomfort—Sicca Symptoms Inventory (PROFAD-SSI). SF-36: Short-form 36-item Health Survey. SF-36 BP: SF-36 Bodily pain domain. MCS: mental component summary score. PCS: physical component summary score.
a Stim SM/SL improved in patients with baseline SWSF N0.1 ml/min (n= 2).
b Median follow up time.
c In 15/28 patients, reported in Meiners et al. [10].
d No signiﬁcant change in control group, compared to baseline.
e Deterioration in control group, compared to baseline.












67G.M. Verstappen et al. / Clinical Immunology 182 (2017) 62–71In a sub-analysis of the TEARS study, parotid parenchyma echostructure
improved in 50% of the rituximab-treated patients versus 7% in the
placebo group, visualizing histological changes induced by rituximab [33].
In summary, there seems to be a beneﬁcial effect of rituximab on
salivary gland function and structure, but the effect size is small and
varies between studies. Echostructure of the gland seems to improve
by rituximab, in linewith the histological effects. The observed decrease
in glandular B cells and (partial) restoration of the ductal epithelium in
patients after treatmentmay contribute to the increase in salivary ﬂow,
but additional factors that affect salivary ﬂow in pSS patients need to be
identiﬁed. Lastly, it should be considered that severe destruction of
parenchyma may not be reversed by immunomodulatory treatment,
but such treatment could halt further damage in patients with residual
gland function.
Tear gland function was assessed by Schirmer's test in most studies.
Only one out of seven studies showed signiﬁcant improvement in
Schirmer's test after treatment (Table 3) [7]. The TEARS study showed
a stable Schirmer's test result in the rituximab group, whereas the place-
bo group tended to deteriorate [8]. Of note, Schirmer's test may not be
suitable to detect small changes over time, as it shows low to moderate
reliability [42]. Measurement of the epithelial integrity of the ocular
conjunctiva by rose Bengal or lissamin green, and cornea by ﬂuorescein
staining is more reliable to evaluate keratoconjunctivitis sicca [43].
Interestingly, studies using these ocular surface staining methods did
show improvement after treatment [4,11]. This improvement may be
caused by effects of rituximab on tear gland morphology and function,
composition of tear ﬂuid, as well as effects on the inﬂammatory micro-
environment of the ocular surface. For example, B cell-derived IL-6 levels
in tears correlate with the severity of ocular surface disease, reﬂected by
a higher extent of ocular pain, irritation and staining [44]. More
knowledge about the effect of rituximab on lacrimal gland inﬂammation
would be valuable, and ocular surface staining should be evaluated in all
clinical studies, instead of using Schirmer's test only.
Besides objective measures of dryness, patient-reported outcomes
(PROs) with visual analogue scales (VAS) were used in most studies to
assess subjective symptoms. Positive results on total dryness scores or
subscores for oral and ocular dryness were seen in most studies
(Table 3). Although no decrease in dryness VAS was seen in de
TRACTISS study, improvement was seen in the TEARS study [8,9]. VAS
dryness scores improved signiﬁcantly among patients in the rituximab
group, although b30 mm, which was set as minimum to achieve
the primary end-point. Furthermore, in a post-hoc analysis, the SS
Responder Index (SSRI) was developed, which includes VAS scores for
fatigue, oral dryness and ocular dryness, as well as UWS and ESR.
Using this composite endpoint, the proportion of patients with a 30%
improvementwas signiﬁcantly higher in the rituximab group, compared
to the placebo group [45].
Altogether, both subjective symptoms and objective measures of
dryness seem to improve or at least stabilize during rituximab treatment
in most studies. These ﬁndings are in accordance with histological
improvements observed in the salivary glands. A lack of robust objective
tests and the poor correlation between objective tests and symptoms in
pSS may underlie the reported variation in study results [46].
4.2. Effects on extraglandular manifestations
Fatigue has a major impact on quality of life in pSS patients and is
therefore an important target for treatment. However, fatigue is a
complex and poorly understood feature of the disease and can only be
measured subjectively [47]. Most studies measured fatigue by VAS, but
more detailed instruments such as the multi-dimensional fatigue
inventory (MFI) and the Proﬁle of Fatigue and Discomfort (PROFAD)
questionnaire were also used. Importantly, most studies show that
fatigue is reduced in pSS patients. All studies, except for the TRACTISS
study and a small group of patients with advanced disease and MALT
lymphoma, showed a positive effect of treatment on fatigue (Table 3).The largest decrease in fatigue is often seen at early time points (week
4 in Meijer et al. and week 6 in the TEARS study). This may explain
why no effect was seen on fatigue in the TRACTISS study, as the ﬁrst
visit in this study was scheduled in week 16. Results at early time points
may have been biased by initial prednisone treatment to prevent
infusion reactions. However, fatigue also improved in the open-label
study by Devauchelle-Pensec et al. where no initial prednisone
treatment was given [15]. In summary, although the effect size is small,
most studies did show improvements in fatigue. In contrast, symptoms
of arthralgia and tendomyalgia do not seem to be ameliorated during
rituximab treatment (Table 3).
Rituximab is often used off-label to treat severe systemic manifesta-
tions of pSS. The effect of rituximab on systemic disease activity was
assessed by ESSDAI in several studies, including a prospective registry
study of off-label treatmentwith rituximab (Table 3). Substantial hetero-
geneity exists within and between study populations regarding systemic
disease activity (Table 2). A signiﬁcant decrease in ESSDAI score follow-
ing treatment was seen in the RCT of Meijer et al., as reported by
Moerman et al., as well as two open label trials and the registry study
[4,7,8,48,49]. Improvement was predominantly seen in the glandular,
articular, hematological and biological domains [5], possibly because
these ESSDAI domains are more likely to change [50]. The efﬁcacy of
rituximab on articular involvement was also conﬁrmed using the
28-joint disease activity score (DAS-28) [51]. Results from the registry
study and extrapolation of efﬁcacy data from other autoimmune
conditions further support the use of rituximab in pSS patients with
vasculitis and pulmonary involvement [48,52]. Therefore, these speciﬁed
clinical settings for rituximab treatment were recently included in the
clinical practice guidelines of the Sjögren's Syndrome Foundation [52].
In contrast with earlier ﬁndings, no signiﬁcant effect on ESSDAI score
was seen in the TEARS and TRACTISS trials [8,9]. Whereas a lack of effect
in the TRACTISS study can be explained by relatively lowbaseline ESSDAI
scores (mean 5.3±4.7 for the rituximab group), themean baseline score
in the TEARS study was 10 ± 7. Of note, in the TEARS study, the ESSDAI
was determined retrospectively, which may inﬂuence the accuracy and
reliability. Furthermore, in the TEARS study, the prevalence of baseline
involvement in the domains that show the highest sensitivity to change,
e.g. glandular, articular, hematological and biological domains, was 29%,
48%, 38% and 57%, respectively [8]. These percentages are relatively low
in comparison to the study by Moerman et al. [49], in which these
domains were active in 70%, 80%, 55% and 85% of patients, respectively
(unpublished data). Meiners et al. and Carubbi et al. also reported a
higher rate of involvement of most of these domains at baseline [5,7].
In conclusion, four prospective studies have shown beneﬁcial effects of
rituximab on systemic involvement [5,7,48,49]. The lack of effect in
recent trials may be explained by low systemic involvement at baseline
or heterogeneity in clinical systemic involvement.
4.3. Effects on quality of life
Several studies investigated the effect of rituximab treatment on
quality-of-life using the 36-Item Short Form Health Survey (SF-36).
Effects of rituximab treatment were seen in several studies in different
domains of the SF-36, but with a large variability between studies
(Table 3). Interestingly, vitality was often improved by treatment.
However, the TEARS and TRACTISS trials did not observe a signiﬁcant
effect of rituximab treatment on SF-36 scores, compared with placebo.
This is consistent with ﬁndings that subjective symptoms improved
only slightly (TEARS) or not at all (TRACTISS) in the rituximab group,
as subjective symptoms are strong predictors of health-related quality-
of-life in pSS patients [53].
5. Predictors of response to rituximab
As described in the previous section, the efﬁcacy of rituximab varies
substantially between studies. Therefore, it is important to detect
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respond to rituximab treatment. Several predictors of good clinical
response to rituximab have, for example, already been identiﬁed in RA
and SLE. In RA, these factors are RF or anti-CCP positivity, elevated
serum IgG, low IFN activity, lower serum levels of BAFF and lower
numbers of circulating plasmablasts [54]. Furthermore, the degree of B
cell depletion was positively associated with clinical response in both
RA and SLE [55,56]. SLE patients with a low-afﬁnity FcγRIIIa genotype
have less effective B cell depletion, as antibody-dependent cellular
cytotoxicity, mediated by FcγRIIIa-positive effector cells (mostly NK
cells), is impaired [57]. This genotype results in lower binding afﬁnity
of FcγRIIIa to anti-CD20 antibodies that are bound to the target B cells.
Whether this FcγRIIIa genotype is also present in a subgroup of pSS
patients is not known.
In pSS, some predictors of response to rituximab were evaluated.
Baseline expression of B cell-related transcripts and presence of the IFN
signature in blood or minor salivary glands were not associated with
clinical response to rituximab in pSS [16,58]. Devauchelle-Pensec et al.
did identify some candidate transcripts, but these need further validation
[58]. Concerning response biomarkers in serum, lower serumBAFF levels
at baseline were associated with clinical response to rituximab in pSS
patients, as deﬁned by a ≥ 30% improvement in at least two items of
the SSRI [26]. As mentioned earlier, high BAFF levels may enhance the
survival (and prevent the depletion) of autoreactive B cell clones,
residing in glandular tissue and/or bone marrow. Besides lower BAFF
levels, responders to rituximab –based on the SSRI– seemed to have
lower baseline B cell activity, as reﬂected by a signiﬁcantly lower B
cell proportion within the glandular inﬁltrate in the labial salivary
glands and lower levels of serum anti-SSA and FLCs [26]. Responders
also had a lower focus score (median 0.3) and a lower salivary gland
ultrasonography grade at baseline, compared with non-responders
[26,59]. Based on these characteristics, responders may have less
irreversible gland destruction and respond to rituximab based on SSRI
improvement, since VAS dryness scores and UWS are two of the ﬁve
measures that constitute the SSRI.
Using a different deﬁnition of clinical response, i.e., a decrease of ≥3 in
the ESSDAI, we have shown that both baseline absolute numbers of B
cells and the B cell proportion in parotid gland tissue are higher in
responders versus non-responders [25,60]. Explanations for the
apparent discrepancy between the study of Cornec et al. and our study
have been extensively discussed elsewhere [60,61]. Our ﬁndings that
high absolute numbers and proportions of B cells in the parotid gland
are associated with ESSDAI response suggest that the number of B cells
in the target tissue inﬂuences systemic disease activity. Likewise, the B
cell proportion in the labial gland positively correlates with markers of
systemic B cell hyperactivation [62]. Together, these data indicate that
rituximab may be effective in either patients with low salivary gland
inﬂammation, to prevent further glandular damage, or in patients with
high numbers of inﬁltrated B cells and high systemic disease activity, to
ameliorate activity in speciﬁed ESSDAI domains.
6. Why does the efﬁcacy of rituximab vary between studies?
As discussed in the previous paragraphs, results from several trials of
rituximab treatment for pSS vary. First, the use of different inclusion
criteria, leading to differences in baseline patient characteristics, may
explain part of this variation. Since rituximab has shown to –at least–
halt further deterioration of glandular function, compared with placebo,
treating patients early in the disease process may prevent progression of
irreversible damage to the glands. Therefore, the majority of the studies
incorporated a limited disease duration (range 2–10 years) as an
inclusion criterion, but still there are large differences in disease duration
between the study populations. Besides disease duration, patients
characteristics such as mean age, IgG levels, and salivary ﬂow also differ
among study populations. For example, mean age is ±10 years lower in
the studies by Meijer et al. and Carubbi et al., and mean IgG is higher inthe study by Meijer et al., compared to other studies [4,7]. In
addition, there may be other unspeciﬁed patient characteristics that
inﬂuence treatment response. For example, ±80% of pSS patients show
poor correlation between reported ocular dryness symptoms and
objective parameters of gland function, caused by either under- or
over-reporting of symptoms [46]. The number of patients under- or
over-reporting their symptoms included in a trial may inﬂuence the
results. Moreover, a study by Lendrem et al. identiﬁed four phenotypic
clusters using hierarchical clustering of patient-reported pain, fatigue,
dryness, anxiety and depression, and found signiﬁcant differences in
IgG, lymphocytes, ESR, ESSDAI score, and UWS between groups [63].
Presumably, these groups may show different responses to rituximab
treatment.
Another possible cause of discrepancies between studies is the use of
(stable) background medication. In the TEARS and TRACTISS studies,
respectively 51% and 68% of the patients used either concomitant
DMARDs (mostly hydroxychloroquine) or prednisone (Table 1).
Hydroxychloroquine and prednisone both have signiﬁcant effects on
the immune system, making it more difﬁcult to show additional effects
of rituximab.
Differences in statistical analysis may also contribute to the variation
in reported outcomes. Several studies use paired tests between baseline
andmultiple time points, whereas speciﬁcmethods for longitudinal data
analysis are available that increase statistical power and reduce multiple
testing problems. Generalized estimating equations (GEE), for example,
take into account the fact that repeated measurements within one
individual are correlated and GEE is therefore a more powerful tool to
detect even small changes over time.
Finally, discrepancy between studies is also caused by the use of
different outcome measures. No consensus has been reached about
the ideal combination of outcome measures to measure treatment
efﬁcacy in pSS. The two large RCTs (TEARS and TRACTISS) have used
change in subjective symptoms (VAS scores) as primary outcome
measures [8,9]. Subjective symptoms such as fatigue and sicca
symptoms account for a great loss in quality of life and are indeed an
important target for treatment. However, the sensitivity to change of
these outcomemeasurements has not been validated, and the response
goals were set quite high (30 mm change in 2 out of 4 VAS scores in
TEARS, 30% change of either oral dryness or fatigue VAS score in
TRACTISS). These goals may have been too high, considering that the
ESSPRI has a minimal clinically important improvement of 1 point
(out of 10) or 15% change. Sensitivity to change may be improved
by the use ofmore precise PROs, such as the Patient-ReportedOutcomes
Measurement Information System (PROMIS), developed by the
National Institutes of Health [64]. Importantly, there is a poor correla-
tion between subjective and objective measures of dryness in pSS
[46]. Until we are able to understand these discrepancies, subjective and
objective measurements of dryness should be equally weighted in the
evaluation of treatment efﬁcacy. In line with this notion, Cornec et al.
proposed a new data-driven composite outcome which combines objec-
tivemanifestations and subjective symptoms, the SSRI [45]. This outcome
was established by combination of ﬁve outcome measures that were
improved by rituximab in the TEARS trial. Although the combination of
subjective and objective measures as primary outcome is of interest, the
SSRI needs to be reﬁned and validated in other clinical studies.
For objective measurement of systemic activity in pSS, introduction
of the ESSDAI in 2010 has been a big step forward [65]. Before that, trials
did not have a validated tool to assess the effect of rituximab treatment
on systemic disease activity. In later trials, most improvement was seen
in domains with the highest activity at baseline [5] and a minimal
clinically important improvement in ESSDAI of at least three points
was determined [66]. Recent trials in pSS have therefore focused on
including patients with moderate-to-high ESSDAI scores (≥5), to be
able to show an effect on extraglandular manifestations.
Although the ESSDAI has been validated and is now being used in
most clinical trials, there are also disadvantages regarding the use of
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domains show sensitivity to change [50]. Consequently, even in
populations with comparable mean ESSDAI scores, differences in which
ESSDAI domains are active at baseline may greatly inﬂuence response
to rituximab. To prove efﬁcacy of rituximab on systemic disease activity,
future trials should therefore include patients with moderate-to-high
ESSDAI scores and activity in at least one of the domains that is likely
to change (biological, articular, hematological, pulmonary, and glandular
domains). Prospective use of speciﬁc indices for separate domains, such
as the DAS-28 for articular involvement, may provide more detailed
information on efﬁcacy. For example, it is difﬁcult to detect moderate
changes in patients with high baseline IgG levels, using the biological
domain of the ESSDAI. Additionally, researchers should be aware of the
complexity of ESSDAI, which needs to be completed by rheumatologists
who are trained and experienced in doing so. In a multi-center setting,
this may not always be the case. A more detailed user guide has
been published, which may increase the accuracy of the ESSDAI [67].
Considering that rituximab shows effect in several domains of the
ESSDAI, patients with high ESSDAI scores may be the target population
that we should aim for. Future trials should explore composite
endpoints, which include selected domains of the ESSDAI score, besides
subjective symptoms and gland function.
7. Conclusions and future directions
Rituximab shows beneﬁcial effects on B cell activity, glandular
morphology, dryness, fatigue and several extraglandular manifestations
in pSS patients. Although two large RCTs did not meet their primary
endpoint, the sensitivity to change of their subjective endpoints may
be limited. Future trials should evaluate clinical and biological predictors
of response and explore the use of composite endpoints such as the SSRI.
We believe that there is still room for new trials with anti-CD20
biologicals, as well as with other B cell-targeting therapies, such as
anti-CD22 or anti-BAFF/Blys antibodies for the treatment of pSS, in
well-deﬁned populations with moderate to high ESSDAI scores. At the
same time, data on long-term (N1 year) efﬁcacy of rituximab and
preventive effects on development of extraglandular manifestations
and/or lymphoma are needed and may support the use of rituximab in
pSS. The effectiveness of pSS has not been proven for all pSS patients,
but in our opinion, rituximab is of great value to treat patients with
systemic manifestations of pSS and we should not throw the baby out
with the bath water.
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